Natera, a genetic testing firm, and Aveta Biomics, a cancer drug developer, have partnered on a late-stage study of an experimental therapy for head and neck cancer. The study aims to improve how patients’ response to treatment is monitored.
Study Details
The study will test Aveta’s APG-157, an experimental oral therapy designed to help the body fight tumors, in patients with locally advanced head and neck cancer. Natera’s Signatera test will be used in the study to assess molecular residual disease and treatment response, serving as a secondary endpoint.
The companies said the test will be used before, during, and after treatment to monitor patients’ response. The study will enroll about 826 patients globally, including in North America, Europe, Asia-Pacific, and Australia.
The trial is expected to begin enrollment in the second half of 2026, the companies said. This study builds on data from a mid-stage trial showing the therapy helped control tumors and showed encouraging survival outcomes.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
